Mobile health devices for screening and detection of common heart condition

NewsGuard 100/100 Score

A new study, presented as 'Late Breaking Science' at the European Society of Cardiology (ESC) annual congress and published in the Journal of the American College of Cardiology, highlights the feasible use of mobile health (mHealth) devices to help with the screening and detection of a common heart condition.

Atrial fibrillation (AF) is a heart rhythm condition that causes an irregular and sometimes, abnormally fast heart rate. In AF, the heart's upper chambers (atria) contract randomly and sometimes so fast that the heart muscle cannot relax properly between contractions. This reduces the heart's efficiency and performance - but also leads to a higher risk of blood clots.

AF is the most common heart rhythm disturbance, affecting around one million people in the UK. People with AF are at increased risk of having a stroke and dying, as well as heart failure and dementia.

Currently, low detection due to lack of visible symptoms and nonadherence are major problems in current management approaches for patients with suspected AF.

Photoplethysmography technology

mHealth devices, such as fitness trackers, smart watches and mobile phones, may enable earlier AF detection, and improved AF management through the use of photoplethysmography (PPG) technology.

PPG is a simple and low-cost optical technique that can be used to detect blood volume changes in the microvascular bed of tissue. It is often used non-invasively to make measurements at the skin surface.

Researchers, led by Associate Professor Guo from Chinese PLA General Hospital in Beijing, and Professor Gregory Lip, Lead for the Liverpool Centre for Cardiovascular Science/Price-Evans Chair of Cardiovascular Medicine at University of Liverpool, aimed to determine the feasibility of AF screening in a large population-based cohort using smart devices with PPG technology, combined with a clinical care AF management pathway.

As part of the study AF screening was performed with smart wristbands or watches using PPG technology made available for the population aged over 18 years across China for approximately seven months (October 26, 2018 to May 20, 2019).


Overall 187,912 participants used smart devices to monitor their pulse rhythm. During this time 424 (0.23%) of the individuals received a 'suspected AF' notification. Of those 227 (87%) were confirmed as having AF by health providers and other secondary examinations. These patients were provided with therapy and successfully anticoagulated.

Associate Professor Guo, said:

Based on our present study, continuous home-monitoring with smart device based PPG technology could be a feasible, cost-effective approach for AF screening. There were 95% patients following entry into a program of integrated AF care, and approximately 80% of high risk patients were successfully anticoagulated. This would help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications."

Professor Lip, said:

Improved AF care requires early detection and the opportunity for streamlined management decision-making. Better detection can be followed by implementing the priorities of AF management, which is as 'easy as ABC': Avoid stroke; Better symptom optimization; Cardiovascular and risk factor management."

Journal reference:

Guo, Y. et al. (2019) Mobile Health Technology for Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices: The HUAWEI Heart study. Journal of the Amercian College of Cardiology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers find beneficial effects of a novel drug in the management of myocardial infarction